Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
International Journal of Environmental Research and Public Health|March 6, 2021
Plasma Xanthine Oxidoreductase Activity Is Associated with a High Risk of Cardiovascular Disease in a General Japanese PopulationYuka Kotozaki, Mamoru Satoh, Kozo Tanno, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 22, 2023
Delayed-Onset Organ/Space Surgical Site Infection Worsens Prognosis in High-Risk Stage II and III Colorectal CancerJun Okui, Kohei Shigeta, Yujin Kato, et al.Biorxiv : the Preprint Server for Biology|November 14, 2023
Preventing NK cell activation in the damaged liver induced by cabozantinib/PD-1 blockade increases survival in hepatocellular carcinoma modelsSatoru Morita, Hiroto Kikuchi, Grace Birch, et al.Hepatology (Baltimore, Md.)|August 6, 2019
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular CarcinomaKohei Shigeta, Meenal Datta, Tai Hato, et al.Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.Annals of Surgery|August 13, 2025
International Validation of a Recurrence Risk Model for Stage II Colon Cancer: The SPHERE StudyKohei Shigeta, Shodai Mizuno, Doruk Orgun, et al.Journal for Immunotherapy of Cancer|November 25, 2020
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinomaKohei Shigeta, Aya Matsui, Hiroto Kikuchi, et al.Annals of Surgery|October 12, 2023
Stratification of Stage II Colon Cancer Using Recurrence Prediction Value: A Multi-institutional International Retrospective StudyShodai Mizuno, Kohei Shigeta, Yujin Kato, et al.Gut|January 12, 2021
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinomaShuichi Aoki, Koetsu Inoue, Sebastian Klein, et al.Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.Pageof 4